top of page


Jellinger AHA/ACC Guidelines 2018
Lipid Guidelines

Research, slides, lectures, case studies and opinion perspectives authored by expert global leaders

  • A Longitudinal Preliminary Study of Addiction-Like Responses to Food and Alcohol Consumption Among Individuals Undergoing Weight Loss Surgery
Nicole Avena, PhD
Full Article               Slides
  • Binge Eating and Reward Sensitivity: Contributions to Obesity and Dysregulated Brain Reward Circuitry
Commentary with full article and slides from Nicole Avena, PhD
Commentary               Full Article               Slides
  • 2018 AHA/ACC Cholesterol Guidelines
Commentary from Paul S. Jellinger, MD, MACE
  • Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
  • REDUCE-IT: Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia 
   VIEW FULL ARTICLE HERE                                          VIEW NEJM VIDEO
Commentary from
Howard S. Weintraub, MD, FACC, FASPC
Summary from
Eliot A. Brinton, MD, FAHA, FNLA
​Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?     
             VIEW ARTICLE
  • Adequately powered clinical trials of sufficient duration are now underway to test the
    cardiovascular benefits of omega-3 fatty acids as well as novel fibrates. These ongoing
    outcomes trials will provide key insights into reducing residual CV risk.
Article with summary and slides from R. Preston Mason, PhD
Full Article             Summary              Slides
Article: New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease
  • EVAPORATE will be the first study using serial cardiac CTA to evaluate the effects of icosapent ethyl on atherosclerotic plaque as an adjunct to statin therapy in a North American population with persistent high TG levels (200-499 mg/dl), and will assess whether these effects correlate with lipid changes and inflammatory markers.
Article and slide presentation by Matthew J. Budoff, MD
Click here             Slides
  • The role of microRNA (miRNA) in the pathophysiology of diabetes and CVD has been of emerging interest in recent years.  The goal of this study was to identify miRNAs that may be related to human insulin sensitivity and associated metabolic syndrome risk factors such as dyslipidemia and elevated blood pressure. 
Article and slide presentation by W. Timothy Garvey, MD
Click here             Slides
  • IMPROVE-IT Update by Diabetes Status, an article by Paul D. Rosenblit MD, PhD, FACE, FNLA
Click here
  • AACE 2017 Guidelines



Expert Commentary by Paul S. Jellinger, MD, MACE

Click here

  • The 2017 AACE/ACE Guidelines for the Management of Dyslipidemia and Prevention of Cardiovascular Disease provided important and groundbreaking new treatment goals. These guidelines were the first anywhere to establish an “Extreme Risk” category with an LDL goal of <55 mg/dl. Prior to this document “Very High Risk” patients from all published guidelines proposed either no specific LDL goal or an LDL goal of <70mg/dl. The "Extreme Risk" category is validated by both the IMPROVE-IT and FOURIER trials and supported by several large meta-analysis including those from the Cholesterol Treatment Trialists’ 2010 Collaboration (CTT 2010) and Boekholdt 2014. Numerous prospective trials in the past have strongly suggested that "lower is better” pointing to further CAD event reduction with LDL levels well below 50 mg/dl.


The Risk Categories including Extreme Risk are noted in the table below. Other important contributions are the emergence of coronary artery calcification (CAC) as a useful tool for risk stratification and the strongest predictor of CVD in low risk patients, recommendations for risk assessment in Type 1 diabetes, discussion of FH, lipid screening recommendations for children and adolescents and the effectiveness and appropriate use of PSCK-9i agents.


The Lipid Guidelines Executive Summary ( is followed by an extensive Evidence Base/Source Document with nearly 700 evidence ranked references.

Click here

  • Perspectives on Diabetes and Dyslipidemia -  a 3 part series available to download

Zachary Bloomgarden, MD, MACE, Clinical Professor, Icahn School of Medicine at Mount Sinai

Editor, Journal of Diabetes, shares current information on the management of type 2 diabetes

  • Guidelines

  • Diabetes and atherosclerosis

  • Effects and effectiveness of lipid-lowering treatments

Part 1

Part 2

Part 3

  • Lipid lowering agents for both primary and secondary prevention of coronary events remain underused by high-risk patients and health-care providers. Calcium scoring improves patient compliance. Slide presentation by Matthew Budoff, MD, FACC, FAHA

Click here

  • Although the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) and development of therapeutic antagonists represent a major triumph of modern clinical medicine, efforts to implement PCSK9 inhibitors (PCSK9i) in patient care have been sobering. This practical guide examines the barriers and opportunities for the successful application of pharmacological inhibition of PCSK9 in clinical practice through introduction of a new model of care delivery—the PCSK9i clinic.

Circ Res. 2017 Aug 18;121(5):499-501. doi: 10.1161/CIRCRESAHA.117.311532.


Application of PCSK9 Inhibitors in Practice: Challenges and Opportunities.

Kaufman TM1, Duell PB1, Purnell JQ1, Wójcik C1, Fazio S1, Shapiro MD2.

Click here

  • New Guidelines for the Management of Dyslipidemia and prevention of CVD,  a video discussion from Yehuda Handelsman, MD, FACP, MACE, FNLA 

See the video here

  •  2014 Lipid Guidelines, a condensed lecture by Elliot Brinton MD, FAHA, FNLA
bottom of page